UFC FIGHT PASS® to Be Made Available on VIDAA-Powered Hisense and Toshiba Smart TVs
4.6.2021 10:00:00 EEST | Business Wire | Press release
UFC®, the world’s premier mixed martial arts organization, and Hisense, the world-class technology company, today announced a distribution and marketing collaboration centered on UFC FIGHT PASS®, the world’s leading subscription streaming service for combat sports, which will be released on VIDAA-powered Hisense and Toshiba smart TVs.
Starting in August, UFC FIGHT PASS will be distributed on new select Hisense TVs as well as on Toshiba Smart TVs manufactured by Hisense that utilize the VIDAA smart platform, a Linux-based open smart TV operating system that is present on products in more than 120 countries around the world.
UFC FIGHT PASS provides subscribers with access to live UFC events; live local mixed martial arts and combat sports from around the world; original series and historical programming; and the world’s largest fight library, featuring more than 20,000 bouts from dozens of combats sports organizations, as well as every fight in UFC history.
As an official marketing partner of UFC, Hisense branding will be featured in the world-famous Octagon® at select UFC events for the remainder of 2021. In addition, Hisense will be the presenting partner of select UFC digital content distributed across UFC social media platforms in the United Kingdom, Ireland, Europe, and the Middle East.
“We are delighted to partner with Hisense and VIDAA to deliver the incredible combat sports content on UFC FIGHT PASS to more fans than ever before,” said Crowley Sullivan, Vice President and General Manager of UFC FIGHT PASS. “This collaboration is a win-win, as it will help us expand our global reach for FIGHT PASS, while exposing Hisense products to UFC’s fan base in key markets.”
“Partnering with UFC, the world leader in MMA, is a big step in bringing the best sports content to our VIDAA users. I believe that we can grow our businesses faster together, since VIDAA is present in almost every country in the world and UFC is becoming increasingly more popular outside the U.S. as well,” said Guy Edri, Executive Vice President for Business Development for VIDAA.
About UFC®
UFC® is the world’s premier mixed martial arts organization (MMA), with more than 625 million fans and 155 million social media followers. The organization produces more than 40 live events annually in some of the most prestigious arenas around the world, while broadcasting to approximately 900M TV households across more than 175 countries. UFC’s athlete roster features the world’s best MMA athletes representing more than 70 countries. The organization’s digital offerings include UFC FIGHT PASS®, one of the world’s leading streaming services for combat sports. UFC is owned by global entertainment, sports and content company Endeavor, and is headquartered in Las Vegas, Nevada. For more information, visit UFC.com and follow UFC at Facebook.com/UFC, Twitter, Snapchat, Instagram and TikTok: @UFC.
About Hisense
Hisense currently has more than 90,000 employees worldwide, together with 16 industrial parks and 16 research and development centres, which comprise a multinational collaborative research and development system. Its business includes multimedia, home appliances, IT intelligent information systems and the modern service industry, while its products have been exported to over 160 countries and regions. According to an independent research and consultancy firm, Hisense remains the world’s fourth-largest TV maker in terms of unit shipments (per 2020 figures).
About VIDAA
VIDAA is a Linux-based open smart TV operating system. Established in 2014, it has - in just six years - become a strong global contender in the smart TV platform space. In 2020, VIDAA introduced a completely new and revamped user interface named 4.0, which puts users and their way of consuming content at the core of the design. The latest version of VIDAA - U5 was launched in May 2021. VIDAA is preinstalled on new Hisense TVs as well as Toshiba Smart TVs manufactured by Hisense. For more information, visit www.vidaa.com and follow VIDAA on Facebook.com/vidaatv, Twitter, and Instagram at @vidaatv.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005152/en/
Contact information
Press Contact for Hisense:
Lori Luo (Ogilvy PR Team)
Email: lori.luo@ogilvy.com / HisenseGlobal@ogilvy.com
Press Contact for UFC:
Niamh Moran
+44 7800 513 876
nmoran@ufc.com
Press Contact for VIDAA:
Jernej Smisl
+386 31 689 862
jernej.smisl@vidaa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom